 Holly Lindsay
Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 16 | 2024 | 1235 | 2.390 |
Why?
| | Medulloblastoma | 7 | 2024 | 193 | 2.240 |
Why?
| | Cerebellar Neoplasms | 6 | 2024 | 152 | 1.730 |
Why?
| | Central Nervous System Neoplasms | 6 | 2025 | 156 | 1.550 |
Why?
| | Glioma | 9 | 2025 | 395 | 1.410 |
Why?
| | Neoplastic Syndromes, Hereditary | 2 | 2019 | 44 | 1.240 |
Why?
| | Ependymoma | 3 | 2024 | 165 | 1.030 |
Why?
| | Lymphopenia | 1 | 2024 | 62 | 0.860 |
Why?
| | Hemophilia A | 2 | 2014 | 139 | 0.760 |
Why?
| | Neurocutaneous Syndromes | 1 | 2019 | 4 | 0.640 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.640 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 35 | 0.640 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1058 | 0.560 |
Why?
| | Cephalosporins | 1 | 2017 | 46 | 0.530 |
Why?
| | Factor VIII | 2 | 2014 | 98 | 0.530 |
Why?
| | Neoplasm Transplantation | 2 | 2020 | 257 | 0.520 |
Why?
| | Germinoma | 1 | 2016 | 10 | 0.510 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 67 | 0.490 |
Why?
| | Renal Insufficiency | 1 | 2017 | 155 | 0.470 |
Why?
| | Granuloma, Pyogenic | 1 | 2014 | 9 | 0.450 |
Why?
| | Coagulants | 1 | 2014 | 19 | 0.450 |
Why?
| | von Willebrand Disease, Type 2 | 1 | 2014 | 1 | 0.450 |
Why?
| | Child | 26 | 2025 | 21816 | 0.440 |
Why?
| | Mouth Diseases | 1 | 2014 | 45 | 0.440 |
Why?
| | DNA Repair Enzymes | 1 | 2013 | 28 | 0.410 |
Why?
| | Glioblastoma | 3 | 2022 | 343 | 0.400 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 57 | 0.390 |
Why?
| | Adenosine Triphosphatases | 1 | 2013 | 165 | 0.380 |
Why?
| | Colorectal Neoplasms | 1 | 2019 | 791 | 0.370 |
Why?
| | Gene Deletion | 1 | 2013 | 389 | 0.360 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 256 | 0.340 |
Why?
| | Prognosis | 8 | 2025 | 4012 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 868 | 0.340 |
Why?
| | DNA-Binding Proteins | 2 | 2019 | 1501 | 0.330 |
Why?
| | Child, Preschool | 11 | 2025 | 10997 | 0.330 |
Why?
| | Neoplastic Stem Cells | 3 | 2024 | 399 | 0.280 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1796 | 0.260 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2123 | 0.260 |
Why?
| | Humans | 33 | 2025 | 136750 | 0.250 |
Why?
| | Adenocarcinoma | 1 | 2013 | 938 | 0.250 |
Why?
| | Cisplatin | 2 | 2024 | 320 | 0.230 |
Why?
| | Mice, SCID | 4 | 2021 | 366 | 0.230 |
Why?
| | Receptor, trkA | 1 | 2025 | 18 | 0.230 |
Why?
| | Gene Fusion | 1 | 2025 | 27 | 0.230 |
Why?
| | Proton Therapy | 1 | 2024 | 13 | 0.230 |
Why?
| | AC133 Antigen | 1 | 2024 | 19 | 0.220 |
Why?
| | CD57 Antigens | 1 | 2024 | 17 | 0.220 |
Why?
| | Craniospinal Irradiation | 1 | 2024 | 5 | 0.220 |
Why?
| | Gangliosides | 1 | 2024 | 20 | 0.220 |
Why?
| | Adolescent | 11 | 2025 | 21380 | 0.220 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2024 | 94 | 0.220 |
Why?
| | Cochlea | 1 | 2024 | 72 | 0.220 |
Why?
| | MicroRNAs | 2 | 2021 | 692 | 0.210 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5105 | 0.210 |
Why?
| | Infratentorial Neoplasms | 1 | 2024 | 63 | 0.210 |
Why?
| | Methotrexate | 1 | 2024 | 260 | 0.200 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2025 | 214 | 0.200 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1272 | 0.200 |
Why?
| | Neoplasm Invasiveness | 1 | 2024 | 507 | 0.190 |
Why?
| | Pyrimidines | 3 | 2025 | 470 | 0.190 |
Why?
| | Symporters | 1 | 2022 | 66 | 0.190 |
Why?
| | Aurora Kinase A | 2 | 2023 | 56 | 0.190 |
Why?
| | Craniopharyngioma | 1 | 2023 | 74 | 0.190 |
Why?
| | Azepines | 2 | 2023 | 90 | 0.190 |
Why?
| | Spinal Cord Neoplasms | 1 | 2022 | 37 | 0.190 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 51 | 0.180 |
Why?
| | Rhabdoid Tumor | 1 | 2023 | 99 | 0.180 |
Why?
| | Survival Rate | 2 | 2024 | 1962 | 0.180 |
Why?
| | Hearing Loss | 1 | 2024 | 220 | 0.180 |
Why?
| | Male | 15 | 2025 | 67305 | 0.180 |
Why?
| | Gadolinium | 1 | 2021 | 82 | 0.180 |
Why?
| | Pituitary Neoplasms | 1 | 2023 | 190 | 0.170 |
Why?
| | Phenotype | 3 | 2021 | 3189 | 0.170 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2020 | 63 | 0.170 |
Why?
| | Hypothalamic Diseases | 1 | 2020 | 18 | 0.170 |
Why?
| | Female | 16 | 2025 | 72785 | 0.170 |
Why?
| | Legislation, Drug | 1 | 2020 | 80 | 0.170 |
Why?
| | Methylphenidate | 1 | 2020 | 38 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 3 | 2025 | 916 | 0.160 |
Why?
| | Survival Analysis | 3 | 2020 | 1321 | 0.160 |
Why?
| | Neurofibromin 1 | 1 | 2019 | 26 | 0.160 |
Why?
| | N-Myc Proto-Oncogene Protein | 1 | 2019 | 9 | 0.160 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2019 | 25 | 0.160 |
Why?
| | DNA Mismatch Repair | 1 | 2019 | 49 | 0.160 |
Why?
| | Germ Cells | 1 | 2019 | 63 | 0.160 |
Why?
| | Histones | 2 | 2022 | 636 | 0.150 |
Why?
| | Digoxin | 1 | 2018 | 30 | 0.150 |
Why?
| | Multigene Family | 1 | 2019 | 198 | 0.150 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 179 | 0.150 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 172 | 0.150 |
Why?
| | Drug Repositioning | 1 | 2018 | 35 | 0.150 |
Why?
| | Central Nervous System Stimulants | 1 | 2020 | 161 | 0.150 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 399 | 0.150 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 250 | 0.150 |
Why?
| | Young Adult | 6 | 2025 | 13126 | 0.150 |
Why?
| | Enzyme Inhibitors | 1 | 2021 | 839 | 0.140 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 77 | 0.140 |
Why?
| | Systems Biology | 1 | 2018 | 66 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 362 | 0.140 |
Why?
| | Neoplasm Metastasis | 2 | 2021 | 657 | 0.140 |
Why?
| | Infant | 6 | 2025 | 9395 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2025 | 15499 | 0.140 |
Why?
| | Fever of Unknown Origin | 1 | 2017 | 12 | 0.140 |
Why?
| | Mutation | 4 | 2022 | 3947 | 0.130 |
Why?
| | Genetic Testing | 1 | 2019 | 453 | 0.130 |
Why?
| | Quality of Life | 3 | 2023 | 2876 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 288 | 0.130 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 79 | 0.130 |
Why?
| | Radiation Tolerance | 1 | 2016 | 96 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2023 | 3556 | 0.120 |
Why?
| | Adult | 6 | 2025 | 37626 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2016 | 185 | 0.120 |
Why?
| | Heterografts | 1 | 2016 | 138 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 528 | 0.120 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 423 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2020 | 280 | 0.120 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1733 | 0.120 |
Why?
| | Weight Loss | 1 | 2020 | 776 | 0.110 |
Why?
| | Chromosome Aberrations | 1 | 2014 | 155 | 0.110 |
Why?
| | Cell Line, Tumor | 5 | 2021 | 3406 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2412 | 0.110 |
Why?
| | Animals | 10 | 2024 | 36836 | 0.110 |
Why?
| | von Willebrand Factor | 1 | 2014 | 80 | 0.110 |
Why?
| | Mismatch Repair Endonuclease PMS2 | 1 | 2013 | 4 | 0.100 |
Why?
| | Heterozygote | 1 | 2014 | 292 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 809 | 0.100 |
Why?
| | Mice | 7 | 2024 | 17758 | 0.090 |
Why?
| | Chemoradiotherapy | 2 | 2024 | 225 | 0.090 |
Why?
| | Neoplasm Grading | 2 | 2024 | 305 | 0.080 |
Why?
| | Alleles | 1 | 2013 | 890 | 0.080 |
Why?
| | Risk Factors | 1 | 2024 | 10330 | 0.080 |
Why?
| | Treatment Outcome | 4 | 2025 | 10747 | 0.080 |
Why?
| | Mice, Inbred NOD | 2 | 2021 | 600 | 0.070 |
Why?
| | Brain | 2 | 2021 | 2664 | 0.070 |
Why?
| | Recurrence | 2 | 2022 | 1055 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2021 | 2476 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 953 | 0.070 |
Why?
| | Obesity | 1 | 2020 | 2982 | 0.060 |
Why?
| | Epigenesis, Genetic | 2 | 2022 | 657 | 0.060 |
Why?
| | Neoplasms | 1 | 2020 | 2643 | 0.060 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4281 | 0.060 |
Why?
| | Cell Cycle | 2 | 2019 | 601 | 0.060 |
Why?
| | Receptor, trkB | 1 | 2025 | 33 | 0.060 |
Why?
| | Interleukin-7 Receptor alpha Subunit | 1 | 2024 | 12 | 0.060 |
Why?
| | Mucositis | 1 | 2024 | 19 | 0.060 |
Why?
| | Apoptosis | 3 | 2018 | 2552 | 0.060 |
Why?
| | Chromosomes | 1 | 2024 | 107 | 0.050 |
Why?
| | Neutropenia | 1 | 2024 | 146 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 210 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 6031 | 0.050 |
Why?
| | Pyrazoles | 1 | 2025 | 423 | 0.050 |
Why?
| | Dissection | 1 | 2021 | 52 | 0.040 |
Why?
| | Biphenyl Compounds | 1 | 2021 | 63 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2021 | 268 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2021 | 184 | 0.040 |
Why?
| | Morpholines | 1 | 2021 | 122 | 0.040 |
Why?
| | Serial Passage | 1 | 2020 | 3 | 0.040 |
Why?
| | Benzamides | 1 | 2021 | 216 | 0.040 |
Why?
| | Government Regulation | 1 | 2020 | 54 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 321 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2020 | 41 | 0.040 |
Why?
| | Pyridones | 1 | 2021 | 168 | 0.040 |
Why?
| | Thalamus | 1 | 2021 | 107 | 0.040 |
Why?
| | United States Food and Drug Administration | 1 | 2020 | 208 | 0.040 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 2019 | 29 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 74 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 72 | 0.040 |
Why?
| | Oncogenes | 1 | 2019 | 116 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1231 | 0.040 |
Why?
| | Radiation, Ionizing | 1 | 2018 | 80 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 86 | 0.040 |
Why?
| | DNA Copy Number Variations | 1 | 2019 | 182 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2019 | 160 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 96 | 0.040 |
Why?
| | Contrast Media | 1 | 2021 | 462 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2019 | 190 | 0.040 |
Why?
| | DNA Methylation | 1 | 2022 | 640 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 375 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2019 | 327 | 0.030 |
Why?
| | Age Factors | 1 | 2024 | 3286 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2019 | 304 | 0.030 |
Why?
| | Blood-Brain Barrier | 1 | 2018 | 138 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2018 | 319 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2014 | 33 | 0.030 |
Why?
| | Serum Albumin, Bovine | 1 | 2014 | 63 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1044 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1772 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 194 | 0.030 |
Why?
| | Genomics | 1 | 2019 | 788 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1180 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1684 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1396 | 0.020 |
Why?
| | Cattle | 1 | 2014 | 981 | 0.020 |
Why?
| | Mitochondria | 1 | 2018 | 946 | 0.020 |
Why?
| | Models, Biological | 1 | 2019 | 1773 | 0.020 |
Why?
| | Aged | 2 | 2025 | 23800 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2605 | 0.020 |
Why?
| | Middle Aged | 2 | 2025 | 33225 | 0.020 |
Why?
| | Biomarkers | 1 | 2018 | 4145 | 0.020 |
Why?
| | Signal Transduction | 1 | 2018 | 5077 | 0.010 |
Why?
| | United States | 1 | 2020 | 14682 | 0.010 |
Why?
|
|
Lindsay's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|